Jubilant Ingrevia Limited

Jubilant Ingrevia Limited (JUBLINGREA) is a small-cap Chemicals company valued at ₹10,050 crore operating in Specialty Chemicals on the NSE and BSE.

Recent price move

Jubilant Ingrevia Limited last traded at ₹630.9, modestly down 0.28% on the day.

Recent developments

2026-10-01: Jubilant Ingrevia announced the acquisition of to be incorporated companies, which could expand its portfolio and enhance its market position. 2026-08-19: The company acquired a 40% stake in Zettaone Technologies for ₹189.2 crore, and reported a 41% rise in Q1 net profit to ₹110.8 crore. 2026-07-22: Jubilant Ingrevia reported Q1 results with revenue up 25% to ₹1,300 crore and net profit rising 41% to ₹105.82 crore.

Financial performance

The company's business has improved, with annual revenue rising 5.0% and net profit growing 10.7% year-over-year. The latest quarter saw revenue surge 25.3% and net profit jump 41.1% compared to the same quarter a year earlier, driven by strong performance in the quarter. The net profit margin expanded 0.3 percentage points to 6.3%, while return on equity and return on capital employed remained stable at 8.9% and 10.7%, respectively.

Valuation multiples

The stock trades at 57.7 times earnings, 3.31 times book value. It yields 0.8%.

Things to watch

The stock is 19.7% below its 52-week high, indicating a significant pullback from recent peak levels. Promoter shares pledged account for 9.30% of promoter holdings, which may signal liquidity pressures. The company's revenue growth has slowed, with a 3-year CAGR of -2.8% and a 5-year CAGR of 45.0%, suggesting a potential shift in growth trajectory.

Where it stands

Jubilant Ingrevia has delivered strong quarterly results with revenue and profit rising significantly year-over-year, but the stock remains 19.7% below its 52-week high. The company's recent acquisitions and positive developments in the quarter highlight its growth focus, though the 3-year revenue CAGR of -2.8% raises questions about long-term sustainability. The latest quarter's net profit of ₹106 crore marks the highest in the last four quarters.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.